Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms by Histologic Type 2Vascular Diseases 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pathologic Processes 1Paraproteinemias 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Lymphatic Diseases 1Lung Neoplasms 1Lung Diseases 1Liver Neoplasms 1Liver Diseases 1Lip Neoplasms 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1

Interventions

Cisplatin 136Radiotherapy 90Cetuximab 89pembrolizumab 65Fluorouracil 56Docetaxel 56Carboplatin 51Paclitaxel 44Radiotherapy, Intensity-Modulated 37Nivolumab 35durvalumab 19Erlotinib Hydrochloride 18Immunohistochemistry 16Radiation 13tremelimumab 12Gemcitabine 11Surgical Procedures, Operative 10Gene Expression Profiling 10Drug Therapy 10Biopsy 10Albumin-Bound Paclitaxel 10Chemotherapy, Adjuvant 9Capecitabine 9Bevacizumab 9atezolizumab 8Radiosurgery 8Polymerase Chain Reaction 8Neoadjuvant Therapy 8Ipilimumab 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Squamous Cell Carcinoma of Head and Neck × ficlatuzumab × Clear all
NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

University of Arizona

Phase 2 Completed
78 enrolled 16 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02277197 2019-04-18

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Pittsburgh

Phase 1 Completed
14 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡